You are here: Industry Insights > Lonza

News List

Lonza Expands Capsule Mfg. Capacity contractpharma
October 23, 2020
$93 million investment to expand production capacity of capsules in CHI's Capsugel portfolio by 30 billion capsules annually, or 15%.
CD19 CAR-T Therapy Manufactured Using Lonza’s Cocoon Platform contractpharma
September 18, 2020
MOH approves Cocoon Platform to manufacture a CD19 CAR-T cell immunotherapy for Phase II clinical trial for B-cell malignancies.
Lonza Establishes Center of Excellence in Oregon contractpharma
July 09, 2020
Can now provide capsule-based DPI formulations for feasibility studies in as little as 12 weeks.
Lonza Expands Cell Culture Med Portfolio americanpharmaceuticalreview
July 07, 2020
Lonza has expanded its cell culture media portfolio with the addition of the GSv9™ Media and Feeds, providing a fully integrated solution specifically designed to optimize recombinant protein production using Lonza’s GS Gene Expression System®.
Lonza Introduces Capsugel DBcaps Double-blinded Capsules contractpharma
June 16, 2020
Designed to be used as an over-encapsulation tool during clinical phases to overcome blinding challenges.
Anthos, Lonza Partnership to Address Thrombotic Disorders contractpharma
June 15, 2020
Development and manufacturing deal leverages Lonza’s network of process development and GMP-manufacturing facilities across Europe and the US for Abelacimab.
Lonza and CELLINK Join Forces to Offer 3D Cell Culture Workflows contractpharma
June 11, 2020
To meet the needs of cell biologists for enhanced bioprinting of complex 3D human tissue constructs.
Lonza sets new goal to make Moderna COVID-19 vaccine ingredients expresspharma
June 04, 2020
Moderna, which enlisted Lonza in May in a 10-year manufacturing contract, is racing with 100-plus other vaccine projects, having last week dosed initial participants in a 600-patient study.
Lonza and Sanquin partner for commercialisation of specialised MAT reagents for accurate and reliabl europeanpharmaceuticalreview
June 02, 2020
Lonza Sales AG, through its Bioscience Division has joined forces with Sanquin Reagents B.V. to enable drug developers and quality control laboratories to take full advantage of the power of the Monocyte Activation Test (MAT).
Lonza, Sanquin Partner for Commercialization of Specialized MAT Reagents americanpharmaceuticalreview
June 01, 2020
Lonza Sales AG, through its Bioscience Division, and Sanquin Reagents have entered into a strategic partnership.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page